Gilead Sciences, Inc. $GILD Shares Bought by Allworth Financial LP

Allworth Financial LP boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 10.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 46,201 shares of the biopharmaceutical company’s stock after buying an additional 4,208 shares during the quarter. Allworth Financial LP’s holdings in Gilead Sciences were worth $5,122,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in GILD. Cypress Capital LLC acquired a new stake in Gilead Sciences during the second quarter worth about $245,000. Illinois Municipal Retirement Fund increased its stake in shares of Gilead Sciences by 16.2% in the second quarter. Illinois Municipal Retirement Fund now owns 336,208 shares of the biopharmaceutical company’s stock valued at $37,275,000 after purchasing an additional 46,940 shares during the period. Altman Advisors Inc. raised its holdings in shares of Gilead Sciences by 3.4% during the second quarter. Altman Advisors Inc. now owns 21,986 shares of the biopharmaceutical company’s stock valued at $2,456,000 after buying an additional 716 shares during the last quarter. Fountainhead AM LLC boosted its position in shares of Gilead Sciences by 2.7% during the second quarter. Fountainhead AM LLC now owns 4,519 shares of the biopharmaceutical company’s stock worth $501,000 after buying an additional 118 shares during the period. Finally, Fidelis Capital Partners LLC grew its holdings in Gilead Sciences by 12.2% in the 2nd quarter. Fidelis Capital Partners LLC now owns 5,291 shares of the biopharmaceutical company’s stock worth $583,000 after buying an additional 575 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Up 3.7%

Shares of Gilead Sciences stock opened at $122.56 on Wednesday. Gilead Sciences, Inc. has a 12-month low of $86.08 and a 12-month high of $124.61. The firm has a market capitalization of $152.07 billion, a PE ratio of 24.41, a price-to-earnings-growth ratio of 0.81 and a beta of 0.32. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. The stock’s fifty day moving average is $116.79 and its 200-day moving average is $112.48.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.16 by $0.31. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm had revenue of $7.77 billion for the quarter, compared to the consensus estimate of $7.42 billion. During the same quarter in the previous year, the company earned $2.02 EPS. The business’s revenue for the quarter was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be issued a dividend of $0.79 per share. The ex-dividend date is Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.6%. Gilead Sciences’s payout ratio is currently 48.99%.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total value of $295,200.00. Following the completion of the transaction, the chief financial officer owned 157,055 shares of the company’s stock, valued at approximately $18,545,054.40. This trade represents a 1.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction on Tuesday, October 28th. The shares were sold at an average price of $119.39, for a total transaction of $1,193,900.00. Following the sale, the chief executive officer directly owned 581,203 shares in the company, valued at approximately $69,389,826.17. This trade represents a 1.69% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 71,500 shares of company stock worth $8,336,040. 0.27% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on GILD shares. Dbs Bank upgraded Gilead Sciences to a “moderate buy” rating in a research report on Friday, September 5th. Truist Financial restated a “buy” rating and set a $145.00 price objective (up from $127.00) on shares of Gilead Sciences in a research note on Monday, November 3rd. Needham & Company LLC reiterated a “buy” rating and issued a $133.00 target price on shares of Gilead Sciences in a research report on Friday, October 31st. BMO Capital Markets raised their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an “outperform” rating in a research note on Monday, October 20th. Finally, Daiwa Capital Markets raised shares of Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price target for the company in a research note on Tuesday, August 19th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $128.27.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.